

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/BPTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/553570
				Filing Date	October 6, 2005
				First Named Inventor	Kenneth HINDS
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PRJ-013US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-4,179,337	12-18-1979	Davis <i>et al.</i>	
	A2*	US-5,102,872	04/1992	Singh <i>et al.</i>	
	A3*	US-5,320,840	06/1994	Camble <i>et al.</i>	
	A4*	US-5,446,090	08/1995	Harris	
	A5*	US-5,672,662	09/1997	Harris <i>et al.</i>	
	A6*	US-5,880,255	03/1999	Delgado <i>et al.</i>	
	A7*	US-5,942,253	08/1999	Gombotz <i>et al.</i>	
	A8*	US-6,323,311	11-27-2001	Liu <i>et al.</i>	
	A9*	US-6,706,289	03-16-2004	Lewis <i>et al.</i>	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	WO-98/46212-A1	10-22-1998	Amgen, Inc.	
	B2	WO-02/41829-A2	05-30-2002	PR Pharmaceuticals, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Bentley, M. <i>et al.</i> , "PEG Biphalin: A Potent Long-Acting Analgesic," <i>28th International Symposium on Controlled Release of Bioactive Materials</i> , pp. 1287-1288 (2001)			
	C2	Diwan, M. <i>et al.</i> , "Pegylation Enhances Protein Stability During Encapsulation in PLGA Microspheres," <i>Journal of Controlled Release</i> , 73: 233-244 (2001)			
	C3	Diwan, M. <i>et al.</i> , "Stabilization of Recombinant Interferon- α by Pegylation for Encapsulation in PLGA Microspheres," <i>International Journal of Pharmaceutics</i> , 252: 111-122 (2003)			
	C4	Hinds, K.D. <i>et al.</i> , "PEGylated Insulin in PLGA Microparticles. <i>In vivo</i> and <i>in vitro</i> Analysis," <i>Journal of Controlled Release</i> , 104: 447-460 (2005)			
	C5	Hora, M.S. <i>et al.</i> , "Development of a Controlled Release Microsphere Formulation of Interleukin-2," <i>Proceedings of the 16th International Symposium on Controlled Release of Bioactive Materials</i> , 16: 509-510 (1989)			
	C6	Hora, M.S. <i>et al.</i> , "Controlled Release of Interleukin-2 from Biodegradable Microspheres," <i>BioTechnology</i> , 8: 755-758 (1990)			
	C7	Katre, N.V. <i>et al.</i> , "Chemical Modification of Recombinant Interleukin 2 by Polyethylene Glycol Increases its Potency in the Murine Meth A Sarcoma Model," <i>Proc. Natl. Acad. Sci. USA</i> , 84: 1487-1491 (1987)			
	C8	Katre, N.V., "Immunogenicity of Recombinant IL-2 Modified by Covalent Attachment of Polyethylene Glycol," <i>The Journal of Immunology</i> , 144(1): 209-213 (1990)			

Examiner Signature	/Hope Robinson/	Date Considered	07/14/2009
--------------------	-----------------	-----------------	------------

07/14/2009

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/553570
				Filing Date	October 6, 2005
				First Named Inventor	Kenneth HINDS
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	PRJ-013US

	C9	Kim, B.M. et al., "Controlled Release of Pegylated Peptides from Poly(Lactic-Co-Glycolic Acid) Microspheres," <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i> , No. 6175:960-961 (2001)	
	C10	Kim, T.H. et al., "Pegylated Recombinant Human Epidermal Growth Factor (rhEGF) for Sustained Release from Biodegradable PLGA Microspheres," <i>Biomaterials</i> , 23:2311-2317 (2002)	
	C11	Lam, X.M. et al., "Sustained Release of Pegylated Monoclonal Antibody Fragments from Drug Delivery Systems," <i>Controlled Release Society 29th Annual Meeting Proceedings</i> , No. 037 (2002)	
	C12	Lam, X.M. et al., "Integrity of PEGylated Monoclonal Antibody Fragment in Polymeric Matrices," <i>Controlled Release Society 30th Annual Meeting Proceedings</i> , No. 449 (2003)	
	C13	Misicka, A. et al., "Structure-Activity Relationship of Biphenyl. The Synthesis and Biological Activities of New Analogues with Modifications in Positions 3 and 4," <i>Life Sciences</i> , 60(15):1263-1269 (1997)	
	C14	Yip, C.M. et al., "Direct Force Measurements of Insulin Monomer-Monomer Interactions," <i>Biochemistry</i> , 37:5439-5449 (1998)	
	C15	International Search Report Application No. PCT/US04/10995, dated December 1, 2005	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Hope Robinson/	Date Considered	07/14/2009
-----------------------	-----------------	--------------------	------------